Cd34 and cd123 - Open Access .click

Results 71 to 80 of about 5,353 (192)

Passenger variants as pan‐clonal markers of pediatric AML: Implications for molecular MRD

HemaSphere, Volume 10, Issue 8, August 2026.
Abstract A streamlined, sensitive, and universal molecular method for MRD detection in pediatric AML remains an unmet clinical need. Here, we propose a novel approach based on tracking somatic non‐coding passenger variants. Using whole‐genome sequencing (WGS) of diagnostic bone marrow DNA, we identify patient‐specific somatic passenger variants, which ...
Ruth Shiloh +20 more
wiley +1 more source

Supplementary data from Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia

, 2017
Supplemental Table 1. Clinical characteristics of non-APL AML patients with MRD data Supplemental Table 2. Flow cytometry panel for MRD Supplemental Table 3.
Jeffrey L. Jorgensen (15002202) +20 more
core +1 more source

Supplementary Table 3 from A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia

, 2023
Supplementary Table 3. MPFC analysis of total AML bone marrow sample according to FLT3 mutational status.
Francesco Lo-Coco +17 more
openaire +1 more source

Delivery Systems for Therapeutic Genome Editing: Challenges, Innovations, and Future Perspectives

MedComm, Volume 7, Issue 7, July 2026.
Schematic illustration of four emerging CRISPR–Cas delivery platforms defined by distinct design principles and structural features: virus‐mimicking nanosystems (e.g., VLPs), cell‐derived extracellular vesicles, cell‐penetrating peptides, and stimuli‐responsive scaffolds. These platforms enable spatiotemporally controlled delivery of RNPs, mRNA, or DNA
Meijia Yang +9 more
wiley +1 more source

Early Epidemiologic and Immune Predictors of Atopic Dermatitis: Reduced Cord Blood Regulatory B10 Cells in the Munich Atopy Prediction Study (MAPS)

Allergy, Volume 81, Issue 7, Page 2463-2477, July 2026.
In this prospective birth cohort from Munich, comprehensive clinical assessments and longitudinal lifestyle questionnaires were combined with cord blood immune profiling. Infants who later developed AD showed altered cord blood immune signatures, including reduced CD4+ T cells, increased B cells and markedly decreased Breg cells. Epidemiologic factors,
S. Preis +14 more
wiley +1 more source

Image_3_Leukemia Stem Cell Frequency at Diagnosis Correlates With Measurable/Minimal Residual Disease and Impacts Survival in Adult Acute Myeloid Leukemia.tif

, 2022
Acute myeloid leukemia (AML) is a heterogenous disease in which the initiation and maintenance of the malignant clone is blamed on a rare population of leukemia stem cells (LSCs).
Nahla M. Elsharkawy (12372586) +5 more
core +1 more source

Supplementary Figure 1 from A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia

, 2023
Supplementary Figure 1. ROC curve analysis using CD34CD123CD25+ve immunophenotype.
Francesco Lo-Coco +17 more
openaire +1 more source

Supplementary Table 2 from A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia

, 2023
Supplementary Table 2. Characteristics of the AML patients according to FLT3 and NPM1 gene mutational status.
Francesco Lo-Coco +17 more
openaire +1 more source

An Immune Dysfunction Signature Score Predicts Survival in MDS Patients: Insights From a Longitudinal, Multicenter Study

Cancer Science, Volume 117, Issue 7, Page 1921-1934, July 2026.
An immune dysfunction score (IDS) provides independent prognostic information in MDS and CMML, complements current risk models, mirrors disease changes, and reflects underlying immune impairment. IDS may also highlight therapeutic sensitivities, supporting its use as a practical biomarker for risk stratification and clinical follow‐up.
Yu‐Hung Wang +16 more
wiley +1 more source

Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation

Haematologica, 2015
Effects of concurrent inhibition of mTORC1/2 and Bcl-2/Bcl-xL in human acute myeloid leukemia cells were examined. Tetracycline-inducible Bcl-2/Bcl-xL dual knockdown markedly sensitized acute myeloid leukemia cells to the dual TORC1/2 inhibitor INK128 in
Mohamed Rahmani +10 more
doaj +1 more source

3. good health
diseases of the blood and blood-forming organs
humans

interleukin-3 receptor alpha subunit
flow cytometry
antigens, cd34

leukemia, myeloid, acute
female
male